Appendix F

Table S2. ASAS20 and ASAS40 responses according to ADA status at week 30.

	Treatment	n	N	(%)	Odds ratio [1]	95% CI of the odds ratio
ADA positive						
ASAS20	CT-P13 5 mg/kg	14	28	50.0	0.47	(0.14, 1.53)
	INX 5 mg/kg	17	26	65.4		
	Goodness-of-fit test (p-value0.487) [2]	.	.			
ASAS40	CT-P13 5 mg/kg	12	28	42.9	1.45	(0.45, 4.70)
	INX 5 mg/kg	10	26	38.5		
	Goodness-of-fit test (p-value0.939) [2]	.	.			
ADA negative						
ASAS20	CT-P13 5 mg/kg	65	84	77.4	1.15	(0.57, 2.31)
	INX 5 mg/kg	67	90	74.4		
	Goodness-of-fit test (p-value0.488) [2]	.	.			
ASAS40	CT-P13 5 mg/kg	46	84	54.8	1.18	(0.65, 2.15)
	INX 5 mg/kg	45	90	50.0		
	Goodness-of-fit test (p-value0.93) [2]	.	.			

Note: N = the number of subjects with an assessment. n = the number of subjects with the event. (%)= n/N*100. INX = innovator infliximab

[1] The odds ratio was estimated using a logistic regression model with treatment as a fixed effect, and region and baseline BASDAI score as covariates.
An odds ratio of >1 indicates an increased odds in favor of CT-P13 5mg/kg.

[2] The p-value is calculated using the Hosmer-Lemeshow test for the goodness-of-fit of the logistic regression model. The test is significant at the 5% level.